Total: $334.89M | ||||
| ||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
|
| ||||
Acusphere Inc. (ACUS) |
Private placement of stock and warrants |
2.9S and |
$17.9 |
Acusphere sold the shares at $6.25 each, and the warrants are exercisable at $8.50 per share; it expects to complete a second closing of $3.6M later in 2004; SG Cowen & Co. LLC was placement agent (8/2) |
| ||||
AspenBio Inc. (OTC BB: APNB) |
Private placement of units |
N/A |
$1.29 |
In a second closing, AspenBio sold units consisting of 20,000 common shares and 20,000 warrants exercisable for three years at $1.50 per share; the units were sold at $17,500 each (8/19) |
| ||||
BioDelivery Sciences International (BDSI) |
Credit facility |
N/A |
$4 |
BDSI gained access to $4M from an affiliated entity, Hopkins Capital Group II; the debt would mature in March 2006, after which HCG II could convert the debt into stock at $4.25 per share (8/3) |
| ||||
BioPhage Pharma Inc. (Canada; VSE:BUG) |
Private placement of units |
5.31S and |
C$0.552 (US$0.42) |
Each of the 5.31M units, which were sold at C$0.104 each, consists of one share and 0.30 of a warrant; each whole warrant allows the purchase of a common share at C$0.25 each for two years; Carpe DM Inc. provided some contacts in the deal (8/2) |
| ||||
ChondroGene Ltd. (Canada; TSE:CDG) |
Private placement of stock and warrants |
5.263S and |
$5 |
The shares were placed at $0.95 each; placement agent Rodman & Renshaw got a 6% fee and a two-year warrant to purchase 315,790 shares at the same price (8/25) |
| ||||
Eiffel Technologies Ltd. (Australia; ASX:EIF) |
Private placement of stock |
36.4S |
A$3 (US$2.14) |
Eiffel placed the shares at A$0.825 each; sales of about 8.6M of the shares are subject to share-holder approval; Intersuisse Corporate managed the placement (8/06) |
| ||||
Hemispherx Biopharma Inc. (AMEX:HEB) |
Private placement of stock and warrants |
3.6S and |
$7.5 |
Units in the financing were sold at $2.08 each; the five-year warrants are exercisable at $2.86 per share (8/2) |
| ||||
Hybridon Inc. (AMEX:HBY) |
Private placement of stock and warrants |
8.8S and |
$5.1 |
Hybridon sold the shares at $0.58 each to institutional and overseas investors; Great Point Partners LLP and Optima Life Sciences Ltd. bought most of the shares; the warrants are convertible into shares at $0.67 each (8/30) |
| ||||
|
Immunomedics Inc. (IMMU) |
Private placement of stock and warrants |
4.18S and |
$15.1 |
The shares were sold from a shelf registration at $3.61 each; warrants are convertible into shares at $3.97 each no later than Nov. 24, 2004; RBC Capital Markets was placement agent (8/2) |
| ||||
|
ISTA Pharmaceuticals Inc. (ISTA) |
Private placement of stock |
1.57S |
$13.3 |
The shares were sold from a shelf registration to institutional investors at $8.50 each; Banc of America Securities LLC, Thomas Weisel Partners LLC, Lazard Freres & Co. LLC and C.E. Unterberg, Towbin LLC were placement agents (8/6) |
| ||||
MediGene AG (Germany; FSE:MDG) |
Private placement of securities |
ND |
€4 |
Concurrent with MediGene's acquisition of Munich Biotech AG, Munich Biotech shareholders invested €4M in MediGene (8/13) |
| ||||
Mologen AG (Germany; FSE:MGNG) |
Private placement of stock |
0.511S |
€0.818 |
Ahead GmbH purchased the shares at a discount of 5% to the 10-day average price, and now owns 9.1% of Mologen (8/26) |
| ||||
Neuropharma (subsidiary of Zeltia SA; Spain; MSE:ZEL) |
Private placement of stock |
2.06S |
€16 |
Investors purchased 25% of the subsidiary; prior to the deal Zeltia owned 100% of Neuropharma; Banco Banif structured the deal (8/2) |
| ||||
Neutec Pharma plc (UK; LSE:NTP) |
Open offer and placement |
5.28S |
£25.8 |
Applications were received for about 31.4% of the shares in the open offer; the offer was fully under-written by Hoare Govett Ltd. (8/12) |
| ||||
|
Pharmos Corp. (PARS) |
Private placement of stock |
5.58S |
$16.75 |
The shares, covered under a shelf registration, were sold to institutional investors at $3 each; Rodman & Renshaw Inc. and Harris Nesbitt were co-lead placement agents (8/23) |
| ||||
|
Pro-Pharmaceuticals Inc. (AMEX:PRW) |
Private placement of stock and warrants |
2S and |
$6 |
The shares were sold at $3 each to new and existing institutional investors; the five-year warrants are convertible at $4.20 per share; Rodman & Renshaw was placement agent (8/12) |
| ||||
|
Protherics plc (UK; LSE:PTI) |
Open offer and placement |
20.77S |
£10 |
Shareholder purchased about 53% of the shares in the open offer, while the remainder were placed with institutions (8/11) |
| ||||
|
Qiagen NV (the Netherlands; QGENF) |
Private placement of convertible notes |
N/A |
$150 |
The senior unsubordinated convertible notes due 2024 were offered with a coupon of 1.5% and are convertible into common shares at $12.645 per share; purchasers have an option to buy another $22.5M in notes (8/4) |
|
| ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; MSE = Madrid Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
